Objectives
First lines of evidence have shown that metformin inhibits cancer cell growth and prevents cancer occurrence in patients with type 2 diabetes. This study aimed to investigate the hypothesised inhibitory effects of metformin on recurrence of bladder cancer in patients undergoing trans-urethral resection of bladder tumour (TURT).
Methods
This case-controlled clinical trial included 65 patients who were divided into two groups: a metformin group (n = 32) and a control group (n = 33). Patients in the metformin group received two tablets of metformin (500 mg) daily for one year. Descriptive, comparative and inferential tests were used to compare the frequency of tumour recurrence in terms of gender, grade and stage of the previous tumour among the two groups.
Results
There was no significant difference in frequency of tumour recurrence between the metformin and control groups (P >0.05). Although time of tumour recurrence in the metformin group was higher compared to the control group, this increase was not statistically significant (P >0.05). In addition, tumour recurrence had no correlation with gender and grade of tumour. However, an insignificant positive weak correlation was observed between recurrence and stage of tumour only in the control group (P >0.05).
Conclusion
These findings indicate that metformin has no considerable inhibitory effect on recurrence of bladder cancer but may delay tumour recurrence. However, further studies with larger sample sizes and the use of higher doses of metformin for a longer duration of time is suggested to confirm these results.
